National Health Determination under paragraph 98C(1)(b) Amendment 2016 (No. 3) (PB 31 of 2016) (Cth)

PB 31 of 2016

National Health Determination under paragraph 98C(1)(b) Amendment 2016
(No. 3)
_____________________________________________________________________

I, PENNY SHAKESPEARE, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1)(b) of the National Health Act 1953.

Dated    29 April   2016

PENNY SHAKESPEARE
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health

1              Name of Instrument

(1)This Instrument is the National Health Determination under paragraph 98C(1)(b) Amendment 2016 (No. 3).

(2)This Instrument may also be cited as PB 31 of 2016.

2              Commencement  

This instrument commences on 1 May 2016.

3              Amendments to Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)

Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).

Schedule 1            Amendments

1. Schedule 3, after entry for Buprenorphine in the form Transdermal patch 10 mg

   insert in the column headed “Form (strength, type, size, etc.)”:

Transdermal patch 15 mg

1. Schedule 3, after entry for Buprenorphine in the form Transdermal patch 20 mg

   insert in the column headed “Form (strength, type, size, etc.)”:

Transdermal patch 25 mg

Transdermal patch 30 mg

Transdermal patch 40 mg

1. Schedule 3, entry for Oxycodone with naloxone

   insert as first item in the column headed “Form (strength, type, size, etc.)”:

Tablet (controlled release) containing oxycodone hydrochloride 2.5 mg with naloxone hydrochloride 1.25 mg

1. Schedule 3, after entry for Oxycodone with naloxone in the form Tablet (controlled release) containing oxycodone hydrochloride 10 mg with naloxone hydrochloride 5 mg

   insert in the column headed “Form (strength, type, size, etc.)”:

Tablet (controlled release) containing oxycodone hydrochloride 15 mg with naloxone hydrochloride 7.5 mg

1. Schedule 3, after entry for Oxycodone with naloxone in the form Tablet (controlled release) containing oxycodone hydrochloride 20 mg with naloxone hydrochloride 10 mg

   insert in the column headed “Form (strength, type, size, etc.)”:

Tablet (controlled release) containing oxycodone hydrochloride 30 mg with naloxone hydrochloride 15 mg

1. Schedule 4, entry for Esomeprazole and Clarithromycin and Amoxycillin

   insert as first item in the column headed “Form (strength, type, size, etc.)”:

Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin 500 mg (as trihydrate)

1. Schedule 4, omit entry for Prochlorperazine

2. Schedule 4, omit entry for Ramipril